Improving chances for successful clinical outcomes with better preclinical models
Vaccine·
- DOI
- 10.1016/j.vaccine.2017.08.030
- PMID
- 28890194
- PMCID
- —
- OpenAlex
- W2752298121
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article is relevant to vaccine-development pathways for Shigella and ETEC, especially efforts to reduce late-stage clinical failure by improving preclinical screening. Its relevance is indirect and methodological rather than a report of health outcomes.
Structured evidence summary
Research question
The article asks how preclinical animal models can better support screening of Shigella and ETEC vaccine candidates for protective efficacy and how these models relate to later human trial outcomes.
Study design
This is a conference workshop summary/commentary rather than an original experimental study. It reports presentations and a group discussion from the 2016 Vaccines Against Shigella and ETEC (VASE) Conference.
Population and setting
The setting is vaccine research focused on Shigella and ETEC, with emphasis on preclinical animal models used in vaccine development. The abstract does not describe a human study population.
Main findings
The workshop noted that current animal models are being used to assess immunogenicity and protective efficacy, but they need improvement for better alignment with human clinical trial outcomes. It highlighted three priorities: more consistent shared reagents, harmonized models and immunology assays, and preclinical correlates of protection to help choose vaccine candidates for further development.
Public-health relevance
The article is relevant to vaccine-development pathways for Shigella and ETEC, especially efforts to reduce late-stage clinical failure by improving preclinical screening. Its relevance is indirect and methodological rather than a report of health outcomes.
Important limitations
No original experimental results are presented in the abstract, so the evidence is limited to workshop discussion and recommendations. This summary is based only on the supplied single-article abstract and metadata; the original paper would be needed for decision-grade interpretation.
GIDS interpretation
This item is discoverable as a vaccine-preclinical-models workshop paper about Shigella and ETEC, not as surveillance evidence. It provides context for the research area but does not establish a live signal or confirm external observations.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.